Peter Svennilson

Peter Svennilson is a Founder and Managing Partner of The Column Group (TCG) and has worked in venture capital and finance for 35 years. He was the Chairman of Aragon Pharmaceuticals from startup until it was sold to Johnson & Johnson in 2013 and Seragon Pharmaceuticals until it was sold to Genentech/Roche in 2014 and was a board director of NGM Biopharmaceuticals (“NGM” on NASDAQ) and Constellation Pharmaceuticals (“CNST” on NASDAQ). Mr. Svennilson is currently a board director of Revolution Medicines (“RVMD” on NASDAQ), ORIC Pharmaceuticals (“ORIC” on NASDAQ), RAPT Therapeutics (“RAPT” on NASDAQ), Ribon Therapeutics, Carmot Therapeutics, and Circle Pharma. Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies such as Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, SomaLogic, Infinity, and Five Prime. Prior to Three Crowns Capital, he was the Associate Managing Director in charge of European investment banking origination at Nomura in London. Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received an M.B.A. from the Stockholm School of Economics and Finance.